Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-Label, Multicentre, Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01328756 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01328756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01328756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-Label, Multicentre, Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Shire
Phase
Phase 4
Overall status
Completed
Start date
July 7, 2011
Completion date
September 30, 2014
Enrollment
314 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder (adhd)